Smith & Nephew’s (SN) Outperform Rating Reaffirmed at Royal Bank of Canada

Smith & Nephew (LON:SN)‘s stock had its “outperform” rating reaffirmed by investment analysts at Royal Bank of Canada in a research note issued on Tuesday, LSE.Co.UK reports. They presently have a GBX 1,500 ($18.84) price target on the stock. Royal Bank of Canada’s price target suggests a potential upside of 50.48% from the stock’s previous close.

A number of other equities analysts also recently weighed in on SN. Berenberg Bank restated a “buy” rating and issued a GBX 1,450 ($18.22) target price on shares of Smith & Nephew in a report on Thursday, May 2nd. Jefferies Financial Group restated a “buy” rating and set a GBX 1,250 ($15.70) price target on shares of Smith & Nephew in a report on Friday. JPMorgan Chase & Co. lifted their price objective on shares of Smith & Nephew from GBX 1,300 ($16.33) to GBX 1,381 ($17.35) and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Finally, Barclays reaffirmed an “equal weight” rating and issued a GBX 1,150 ($14.45) price target on shares of Smith & Nephew in a research note on Friday, February 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 1,346.20 ($16.91).

Smith & Nephew Trading Up 1.1 %

SN traded up GBX 11.20 ($0.14) during trading on Tuesday, reaching GBX 996.80 ($12.52). 2,497,223 shares of the company’s stock were exchanged, compared to its average volume of 343,671. The firm has a fifty day moving average price of GBX 1,015.60 and a two-hundred day moving average price of GBX 1,036.17. The stock has a market capitalization of £8.72 billion, a PE ratio of 4,153.33, a price-to-earnings-growth ratio of 0.46 and a beta of 0.51. Smith & Nephew has a one year low of GBX 887 ($11.14) and a one year high of GBX 1,316.75 ($16.54). The company has a current ratio of 1.77, a quick ratio of 0.84 and a debt-to-equity ratio of 59.11.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.